Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Agents. Found 201 abstracts

no pagination
Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH, Bachovchin WW, Weiner LM. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Molecular Cancer Therapeutics. 2005 Mar;4(3):351-60.
Held-Warmkessel J. Managing three critical cancer complications. Nursing. 2005 Jan;35(1):58-63; quiz 63-4.
Manne SL, Ostroff JS, Winkel G, Fox K, Grana G, Miller E, Ross S, Frazier T, Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A, Morrow M, Chen JQ, Yager JD, Russo J, Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ, Devlin J, Sherman E, Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, McClatchey AI, Kane AB, Testa JR, Murphy ME, Langer CJ, Mehta MP, Viterbo R, Greenberg RE, Al-Saleem T, Canutescu AA, Dunbrack RL, Serebriiskii IG, Fang R, Latypova E, Hopkins R, Vinson C, Joung JK, Golemis EA. Couple-focused group intervention for women with early stage breast cancer. . J Consult Clin Psychol. 2005 Sep 15;73(4):634-46.
Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clinical Colorectal Cancer. 2005 Jul;5(2):108-13.
Tarn C, Godwin AK. Molecular research directions in the management of gastrointestinal stromal tumors. Current treatment options in oncology. 2005 Nov;6(6):473-86.
Berger AC, Watson JC, Ross EA, Zalatoris A, Hoffman JP. Neoadjuvant therapy and biliary decompression lower biliary and pancreatic juice vascular endothelial growth factor levels in patients with periampullary adenocarcinoma. Am Surg. 2004 Feb;70(2):169-73; discussion 173-4.
Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?. Oncology (Williston Park). 2004 Apr;18(4):479-88; discussion 488, 493.
Einarson MB, Cukierman E, Compton DA, Golemis EA. Human enhancer of invasion-cluster, a coiled-coil protein required for passage through mitosis. Molecular and Cellular Biology. 2004 May;24(9):3957-71.
Langer CJ. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys. 2004 Mar;58(3):991-1002.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Langer CJ. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clinical lung cancer. 2004 Dec;6 Suppl 2:S85-8.
Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Ursulic S, Smyth J. Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. Eur J Cancer. 2003 Sep;39(13):1818-27.
Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003 Apr;21(7):1301-6.
Colice GL, Rubins J, Unger M. Follow-up and surveillance of the lung cancer patient following curative-intent therapy. Chest. 2003 Jan;123(1 Suppl):272S-283S.
Cortellino S, Turner D, Masciullo V, Schepis F, Albino D, Daniel R, Skalka AM, Meropol NJ, Alberti C, Larue L, Bellacosa A. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci U S A. 2003 Dec 09;100(25):15071-6.   PMCID: PMC299910
Eisenberg BL. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors. Oncology (Huntingt). 2003 Nov;17(11):1615-20; discussion 1620, 1623, 1626 passim.
Eisenberg BL, von Mehren M. Pharmacotherapy of gastrointestinal stromal tumours. Expert Opin Pharmacother. 2003 Jun;4(6):869-74.
Haas NB, Smith M, Lewis N, Littman L, Yeslow G, Joshi ID, Murgo A, Bradley J, Gordon R, Wang H, Rogatko A, Hudes GR. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study. Clin Cancer Res. 2003 Jan;9(1):109-14.
Jett JR, Scott WJ, Rivera MP, Sause WT. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest. 2003 Jan;123(1 Suppl):221S-225S.
Meyers MO, Sasson AR, Sigurdson ER. Locoregional strategies for colorectal hepatic metastases. Clin Colorectal Cancer. 2003 May;3(1):34-44.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Agents

Antineoplastic Agents Human therapeutic use 0 (Antineoplastic Agents) dt [Drug Therapy] Male Lung Neoplasms Female drug therapy Non-Small-Cell Lung Carcinoma therapy metabolism Aged Middle Aged pharmacology surgery tu [Therapeutic Use] pathology genetics Clinical Trials Adult ch [Chemistry] methods pd [Pharmacology] Pyrimidines administration & dosage 80 and over Aged Time Factors me [Metabolism] NIH Research Support-Extramural secondary Neoplasm Metastasis Adenocarcinoma Colorectal Neoplasms antagonists & inhibitors Enzyme Inhibitors ai [Antagonists & Inhibitors] Piperazines Survival Rate Neoadjuvant Therapy Quinazolines 0 (Taxoids) mortality Gastrointestinal Neoplasms Molecular Sequence Data Pancreatic Neoplasms Taxoids Apoptosis Protein-Tyrosine Kinase Western Blotting ph [Physiology] US Gov't Research Support-PHS Monoclonal Antibodies Middle Age diagnosis Disease Progression Comparative Study Adjuvant Chemotherapy Protein Conformation Non-US Gov't Support Treatment Outcome Saccharomyces cerevisiae Cisplatin Fibroblasts Amino Acid Sequence Epidermal Growth Factor Receptor Brain Neoplasms Molecular Models Flow Cytometry ae [Adverse Effects] US Gov't Support-PHS Non-US Gov't Research Support Mitosis Sequence Alignment Cell Line EC 2-7-1-112 (Protein-Tyrosine Kinase) ge [Genetics] Biological Tumor Markers Neoplasms Kidney Neoplasms Retrospective Studies Mutation Mice blood Camptothecin Small Interfering RNA Multivariate Analysis toxicity Drug Delivery Systems Adrenal Cortex Hormones Recombinant Fusion Proteins aa [Analogs & Derivatives] DNA Repair Local Neoplasm Recurrence Polyglutamic Acid Seizures Dose Fractionation ep [Epidemiology] EC 27137 (Proto-Oncogene Proteins c-raf) Two-Hybrid System Techniques Catalytic Domain Binding Sites User-Computer Interface Serine Endopeptidases Immunohistochemistry Kinetics C-Reactive Protein Proportional Hazards Models Liver Neoplasms Systems Integration dosage Incidence ai [Antagonists & 951-77-9 (Deoxycytidine) Carrier Proteins Follow-Up Studies G2 Phase Thymine DNA Glycosylase Inappropriate ADH Syndrome Palliative Care et [Etiology] DNA-Binding Proteins Reverse Transcriptase Polymerase Chain Reaction etiology Complementary) 0 (DNA biosynthesis 184475-35-2 (gefitinib) drug effects Cultured Cells Analysis of Variance Algorithms physiopathology 0 (Recombinant Fusion Proteins) Randomized Controlled Trials Catheter Ablation Radiotherapy Alkyl and Aryl Transferases Cell Separation 0 (Adrenal Cortex Hormones) Cell Cycle Proteins Cognition Disorders Platelet-Derived Growth Factor) EC 2-7-1-112 (Receptors Drug Hypersensitivity Antineoplastic Antimetabolites Hepatectomy ad [Administration & Dosage] Gastrointestinal Stromal Tumors Prognosis 0 (Piperazines) Survival
Last updated on Friday, January 03, 2020